Chemoinformaics analysis of (25R)-3beta-hydroxy-5beta-spirostan-12-one
| Molecular Weight | 430.629 | nRot | 0 |
| Heavy Atom Molecular Weight | 388.293 | nRig | 31 |
| Exact Molecular Weight | 430.308 | nRing | 6 |
| Solubility: LogS | -4.996 | nHRing | 2 |
| Solubility: LogP | 4.111 | No. of Aliphatic Rings | 6 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 73 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 31 | No. of Aromatic Carbocycles | 0 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 42 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 27 | No. of Saturated Rings | 6 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 0 |
| nHA | 4 | APOL | 76.3033 |
| nHD | 1 | BPOL | 46.4747 |
| QED | 0.589 |
| Synth | 5.392 |
| Natural Product Likeliness | 3.221 |
| NR-PPAR-gamma | 0.012 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.864 |
| Pgp-sub | 0.002 |
| HIA | 0.005 |
| CACO-2 | -4.891 |
| MDCK | 0.0000653 |
| BBB | 0.95 |
| PPB | 0.917937 |
| VDSS | 1.6 |
| FU | 0.0243703 |
| CYP1A2-inh | 0.013 |
| CYP1A2-sub | 0.578 |
| CYP2c19-inh | 0.053 |
| CYP2c19-sub | 0.953 |
| CYP2c9-inh | 0.132 |
| CYP2c9-sub | 0.126 |
| CYP2d6-inh | 0.001 |
| CYP2d6-sub | 0.81 |
| CYP3a4-inh | 0.145 |
| CYP3a4-sub | 0.618 |
| CL | 25.174 |
| T12 | 0.065 |
| hERG | 0.032 |
| Ames | 0.021 |
| ROA | 0.847 |
| SkinSen | 0.728 |
| Carcinogencity | 0.065 |
| EI | 0.01 |
| Respiratory | 0.833 |
| NR-Aromatase | 0.114 |
| Antiviral | Yes |
| Prediction | 0.767107 |